Close menu

September 20th, 2021 | 10:25 CEST

Drägerwerk, Royal Helium, Bayer: These shares are stepping on the gas

  • Helium
Photo credits:

Chemical products and gases are essential products for industry. These primary products are a good indicator of the current economic situation. Shortages are currently prevalent here as well. We explain why and outline three stocks related to this topic.

time to read: 3 minutes | Author: Nico Popp
ISIN: DRAEGERWERK VZO O.N. | DE0005550636 , ROYAL HELIUM LTD. | CA78029U2056 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Drägerwerk faces a positive future

    The Drägerwerk share is currently taking a short breather. But business at the medical technology company is going exceptionally well. In the pandemic year 2020, both sales and order intake climbed significantly. Drägerwerk is a ventilation specialist and also does good business with anesthesia equipment. Nevertheless, it will not be possible to repeat the record year in this form. That is why the share is currently weakening. In principle, however, Drägerwerk is promising. The pandemic has exposed the weaknesses of the healthcare system and put the focus on necessary investments.

    With a price-earnings ratio (P/E) of around 10, the stock is still not expensive. That opens up the potential for long-term investors in particular. Although the share hardly offers a dividend, at least the prospect speaks in favor of Drägerwerk. Given the shortage of personnel in the healthcare sector and the increasingly ageing patients, technology could be the key to an even better functioning healthcare system. The share is not a high-flyer but remains promising in the long term.

    Royal Helium: Operational success and correction

    Royal Helium is another promising stock. The budding helium producer is benefiting not only from demand from medical technology companies, which use the noble gas in devices for imaging procedures but also from the increasingly important space sector. Royal Helium owns about 400,000 hectares of rights to explore for helium. The project is located in the Canadian district of Saskatchewan and offers several advantages due to its geological features. Since there are few to no carbons in the production, mining in Royal Helium's area can be considered environmentally friendly. The district also requires low royalty rates compared to other regions and a diverse mix of service providers and skilled personnel due to the existing oil and gas industry.

    Having successfully completed three wells in the first few months of the year, Royal Helium drilled the Climax-4 well in recent months, where evaluations are currently underway. However, initial results indicate that the helium deposits in this well could be more significant than in Climax-3. The share has corrected by around 50% since its highs of April above the EUR 0.60 mark; the value could become interesting again. Operationally, the Company has made progress in the meantime. The current level appears favorable to invest in the noble gas with indispensable properties for many industries.

    Bayer: Dull share prices despite innovations

    Like Drägerwerk and Royal Helium, Bayer shares have also suffered in recent months. Over a three-month period, the share price has fallen by around 15% and almost 20% over the year. But what is the reason for this? Fundamentally, things look good for Bayer. While 2020 was a challenging year for the Company, it is now apparent that many of the construction sites of previous years, such as the Monsanto acquisition, could be positive for Bayer in the long term. The seed business fits well with the current inflation debate.

    With innovative pharmacological processes, such as cell and genetic engineering, the Rhinelanders are looking for a big breakthrough. That the Company is innovative in every area is demonstrated, for example, by a corn variety that is largely resistant to extreme weather events. The share price has fallen recently but is also promising given the attractive dividend yield of around 3.5%.

    Bayer thus outperforms the competition from Drägerwerk. While the medical technology specialist offers good products but little imagination, Bayer could soon surprise. The same applies to Royal Helium. The Company is only valued at around EUR 43 million and must therefore be considered speculative. However, the share price performance in the first quarter shows that it also offers excellent opportunities.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by André Will-Laudien on April 8th, 2024 | 07:00 CEST

    Sell AI now and buy turnaround stocks: Nel ASA, Royal Helium, Linde and Plug Power

    • Helium
    • AI
    • renewableenergies
    • chemicals

    The stock market gives and takes away. When it comes to artificial intelligence and high-tech, investors have been able to make gains of up to 600% in recent months. Stocks such as Nvidia and Super Micro Computer are on the hit list of all fund managers worldwide. However, the first quarter is over, and there is no immediate reason to continue buying overpriced AI stocks. Last Thursday saw the first shot across the bow, with the NASDAQ 100 index plummeting by over 2% within three hours. Technically, the upward momentum is already waning, leading to increased profit-taking. If many investors do it simultaneously, it will result in a hefty correction. Do not wait too long; we present some interesting reallocation ideas.


    Commented by Fabian Lorenz on April 3rd, 2024 | 07:15 CEST

    Renk, Super Micro Computer, Royal Helium: SHARES UNSTOPPABLE!

    • Mining
    • Helium
    • AI
    • Defense
    • Technology

    The Renk share is unstoppable. Yesterday, the shares of the defense technology company surged by 7% at its peak. The share is scratching at the EUR 40 mark and has thus more than doubled since the IPO in February of this year. While the share price is being driven by politics, analysts are beginning to lose interest. So, is it time to exit now? The defense industry needs helium just as much as medical technology and quantum computers. Royal Helium is one of the few listed companies in this sector. The Company is currently making the leap from explorer to producer, a move that should benefit the share. Helium is also needed to produce the AI semiconductors used by Super Micro Computer. Microsoft, OpenAI, and Amazon show that the hunger for AI data centers is far from satisfied. They plan to invest over USD 200 billion in new supercomputers.


    Commented by Stefan Feulner on March 20th, 2024 | 07:15 CET

    Pure growth - Super Micro Computer, Royal Helium, Rheinmetall

    • Helium
    • armaments
    • chips
    • AI

    After weeks of chasing records, equities, precious metals, and cryptocurrencies are taking a breather, at least in the short term, ahead of today's decision by the US Federal Reserve. The current key interest rate decision and, above all, the Fed's quarterly projections on economic development, interest rates, and inflation will likely continue to shape events afterwards. The pause will likely be short-lived if positive signals regarding earlier than planned interest rate cuts are announced.